TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03878849: Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Sponsor: Allarity Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT03878849 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03878849 Rescue Dossier →